SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Cell Therapeutics, Inc. Announces Data Safety and Monitoring Board Recommendation to Continue the GOG-0212 Phase 3 Clinical Trial of OPAXIOTM as Maintenance Therapy in Ovarian Cancer